Established cardiovascular disease was required
SELECT enrolled 17,604 adults aged at least 45 with overweight or obesity and preexisting cardiovascular disease, but no history of diabetes. Participants received weekly semaglutide 2.4 mg or placebo in a randomized, double-blind trial. Mean follow-up was 39.8 months. Novo Nordisk funded the study. [1]
The existing-disease requirement is crucial. This is not direct evidence that any otherwise healthy person with excess weight receives the same cardiovascular benefit. A prevention claim should say whether the trial studied people who already had the condition or those who had not developed it.
Keep the combined endpoint visible
The primary endpoint combined cardiovascular death, nonfatal heart attack and nonfatal stroke. It occurred in 6.5% of the semaglutide group and 8.0% of the placebo group, with a hazard ratio of 0.80. Adverse events caused permanent treatment discontinuation in 16.6% versus 8.2%. [1]
The observed difference between the percentages is 1.5 percentage points. A headline describing a 20% reduction refers to the relative hazard estimate, not a 20-percentage-point decrease in everyone’s risk. Both perspectives can be informative, but they should not be exchanged without explanation.
A cardiovascular trial answers a different question
A weight-management study can show a change on the scale without establishing fewer clinical cardiovascular events. SELECT directly counted a defined combination of events over time. That is why it adds a different kind of evidence rather than simply another weight-loss percentage.
The result still belongs to the complete endpoint and study population. It should not automatically be divided into separate claims about each component or extended to every formulation. Nor does this trial compare semaglutide with another active weight-management medicine. A benefit against placebo is not a universal ranking.
The follow-up interval also belongs beside an absolute difference. A risk difference observed over roughly the study period cannot simply be called an annual benefit. Converting it requires additional assumptions. For an appointment, keep the reported proportions and duration together rather than creating a new yearly promise.
Discuss relevance before comparing access
If you have cardiovascular disease, ask your clinician whether the SELECT population and endpoint are relevant to your treatment goals. Bring the actual paper rather than only an advertisement’s percentage. A useful explanation should connect the evidence with your history and existing care.
For a separate look at weight change within this program, see the SELECT weight analysis. Keep insurance questions separate from clinical evidence: a study does not determine your plan’s decision. Our prior-authorization guide helps establish what coverage information must be confirmed, including the exact product and the documentation requested by the insurer.